NASDAQ
06.02.26 | 20:42
12,660 US-Dollar
+1,93 % +0,240
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.01. | Phathom Pharmaceuticals: Stifel bekräftigt "Buy"-Rating nach starkem Umsatzausblick | 7 | Investing.com Deutsch | ||
| 15.01. | Phathom Pharmaceuticals stock maintains Buy rating at Stifel on strong revenue outlook | 4 | Investing.com | ||
| 14.01. | Cantor Fitzgerald reiterates Overweight rating on Phathom stock at $29 | 2 | Investing.com | ||
| 14.01. | Cantor Fitzgerald bestätigt "Overweight" für Phathom und sieht 86 % Kurspotenzial | 6 | Investing.com Deutsch | ||
| 08.01. | Phathom Pharma Shows Sales Strength, Targets 2026 Profitability | 5 | Benzinga.com | ||
| 08.01. | Phathom Pharmaceuticals prices $130 million public offering | 12 | Investing.com | ||
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 08.01. | Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 07.01. | Phathom Pharmaceuticals announces public offering of common stock | 3 | Investing.com | ||
| 07.01. | Phathom Pharma plans public offering after reporting preliminary 2025 results | 1 | Seeking Alpha | ||
| 07.01. | Phathom Pharmaceuticals kündigt nach Kursrallye öffentliches Aktienangebot an | 5 | Investing.com Deutsch | ||
| 07.01. | Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 07.01. | Phathom Pharmaceuticals reports Preliminary Q4 results | 2 | Seeking Alpha | ||
| 07.01. | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | 154 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| 07.01. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.12.25 | Raymond James initiates Phathom Pharmaceuticals stock with Strong Buy rating | 7 | Investing.com | ||
| 04.11.25 | Phathom Pharmaceuticals startet Phase-2-Studie mit VOQUEZNA bei eosinophiler Ösophagitis | 8 | Investing.com Deutsch | ||
| 30.10.25 | Phathom projects $1B GI market opportunity as sales realignment drives 25% revenue growth | 1 | Seeking Alpha | ||
| 30.10.25 | Phathom Pharmaceuticals stock price target raised to $20 by Guggenheim | 2 | Investing.com | ||
| 30.10.25 | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 30.10.25 | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOCRYST PHARMACEUTICALS | 5,392 | +1,70 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 | ||
| SAREPTA THERAPEUTICS | 15,680 | +8,44 % | Sarepta gets New Zealand approval for Huntington's disease trial | ||
| MICROBOT MEDICAL | 1,475 | +7,59 % | Microbot Medical Inc. - 8-K, Current Report | ||
| IMMUNITYBIO | 5,064 | +5,88 % | ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy | ||
| ADAPTIMMUNE THERAPEUTICS | 0,016 | +100,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,126 | +3,58 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| CAPRICOR | 19,000 | -2,96 % | CAPRICOR THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| ABEONA THERAPEUTICS | 4,280 | +2,39 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer | CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,200 | +1,41 % | Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 | ||
| VIR BIOTECHNOLOGY | 7,200 | +4,05 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 65,00 | 0,00 % | Palvella Therapeutics: Clear Street bestätigt Kaufempfehlung im Vorfeld von Studiendaten | ||
| DBV TECHNOLOGIES | 3,520 | -2,90 % | DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 | Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 12,200 | -0,81 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted six newly-hired employees inducement options to purchase an... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,260 | -9,35 % | Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 5,500 | +0,92 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants |
PHATHOM PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,93 % bei einem Aktienkurs von 12,660 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.